You are here: Industry Insights > NICE

News List

NICE rejects Alexion’s rare disease therapy Kanuma pharmatimes
February 16, 2017
The National Institute for Health and Care Excellence has published a final evaluation determination rejecting the use of Alexion's Kanuma to treat infants, children and adults with the rare inherited genetic disorder lysosomal acid lipase deficiency (LAL
NICE approves Incyte’s leukaemia drug for routine NHS use europeanpharmaceuticalreview
February 14, 2017
The National Institute for Health and Care Excellence (NICE) published draft guidance recommending ponatinib (Iclusig, Incyte Corporation) for routine use on the NHS, to treat some patients with chronic myeloid leukaemia and acute lymphoblastic leukaemia.
Pfizer’s breast cancer drug too expensive for NHS europeanpharmaceuticalreview
February 06, 2017
The National Institute for Health and Care Excellence (NICE) has today published draft guidance which does not recommend breast cancer drug palbociclib (Ibrance, Pfizer) for routine funding on the NHS. A full course of treatment costs £79,650.
New NICE ultra-rare disease proposals "not fit for purpose", says BIA pharmafile
January 17, 2017
The BioIndustry Association (BIA) has accused new proposals put forward by the National Institute for Health and Care Excellence (NICE) of being “not fit for purpose” and potentially denying patients from accessing treatments for ultra-rare disease.
NICE approves former CDF kidney cancer drug for NHS use europeanpharmaceuticalreview
January 13, 2017
The National Institute for Health and Care Excellence (NICE), in new draft guidance, has recommended everolimus for treating some people with advanced kidney cancer, a drug which was previously only available through the Cancer Drugs Fund (CDF).
National Institute for Health and Care Excellence (NICE) Issues Final Positive Recommendation for Ga firstwordpharma
January 05, 2017
Amicus Therapeutics announced that the National Institute for Health and Care Excellence (NICE) Highly Specialised Technologies Evaluation Committee (EC) has issued a positive final evaluation determination (FED) for reimbursed patient access to Galafold™

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page